Stereotaxis (STXS)
Builds magnetic-navigation robots and catheters for cardiac electrophysiology.
Something off on this page? Send us feedback.
Builds robotic magnetic-navigation systems and compatible catheters for cardiac electrophysiology, then earns from capital installations, disposable devices, software and service. Its integrated platform is expanding into mechanical robotics for cardiology and neurointervention.
Directs flexible, magnetically responsive catheters and guidewires inside blood vessels using external magnetic fields and computer controls. Genesis and GenesisX support electrophysiology mapping and ablation for arrhythmias, while R-One adds mechanical robotics for coronary and other endovascular procedures.
Sells capital equipment and installation alongside compatible disposable instruments, lab-control software and post-warranty service. Sales reach hospitals directly and through distributors, with recurring revenue tied to clinical use of the installed base; customer revenue is weighted outside the United States.
Relies on regulatory clearance that varies by device and geography, compatibility with third-party lab systems, and outsourced major system subassemblies; final assembly and inspection remain in-house.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 13, 2026 | Piper Sandler | Target | Target: — | Target: $3.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.5M · Total debt $5.2M · Total assets $55.6M · Shareholders' equity $17.5M
- Revenue
- $7.7M
- Operating income
- −$4.6M
- Net income
- −$4.5M
No dividends on record.
| Institutions | 43.13% | 43.21M shares | |
|---|---|---|---|
| 112 holders · as of Jun 30, 2026 | |||
| Insiders | 13.47% | 13.50M shares | |
| 2 holders · as of Aug 19, 2026 | |||
| Strategic holders | 7.29% | 7.31M shares | |
| 1 holder · as of Feb 14, 2022 | |||
| Other | 36.11% | 36.18M shares | |
| remainder | |||
100.20M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dafna Capital Management LLCInstitution | 13.65% | 13.68M | as of Jun 30, 2026 |
Joe KianiInsider | 7.53% | 7.54M | filed Jun 16, 2021 |
Redmile Group, LLCStrategic | 7.29% | 7.31M | filed Feb 14, 2022 |
Daniel Louis KaufmanInsider | 5.94% | 5.96M | filed Aug 19, 2026 |
BlackRock, Inc.Institution | 4.39% | 4.40M | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Johnson & Johnson
CARTO mapping and VARIPULSE PFA contest integrated EP lab spend.
- Boston Scientific
FARAPULSE and OPAL HDx offer an integrated map-and-ablate alternative.
- Medtronic
Affera and Sphere-9 offer integrated dual-energy EP mapping and ablation.
- Abbott
EnSite X and Volt PFA contest EP mapping, catheter and workflow spend.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Stereotaxis | $1.36 | 0.00% | $133.2M | — | — | 4.4 | −12.8% |
| Johnson & Johnson | $268.53 | −0.35% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Boston Scientific | $44.73 | +2.30% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Medtronic | $91.31 | −0.49% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Abbott | $104.27 | +1.25% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Median | 26.9 | 16.6 | 3.5 | +10.3% |